Literature DB >> 8406584

Inhibition of interferon-gamma by an interferon-gamma receptor immunoadhesin.

M Haak-Frendscho1, S A Marsters, S M Chamow, D H Peers, N J Simpson, A Ashkenazi.   

Abstract

Interferon-gamma (IFN-gamma) is an important cytokine which regulates inflammatory and immune response mechanisms. IFN-gamma enhances the presentation and recognition of antigens by inducing the expression of major histocompatibility complex (MHC) proteins, by activating effector T cells and mononuclear phagocytes, and by modulating immunoglobulin production and class selection in B cells. Inappropriate production of IFN-gamma has been implicated in the pathogenesis of several autoimmune and inflammatory diseases and in graft rejection. Here, we describe a recombinant inhibitor of IFN-gamma, termed murine IFN-gamma receptor immunoadhesin (mIFN-gamma R-IgG). We constructed this immunoadhesin by linking the extracellular portion of the mouse IFN-gamma R to the hinge and Fc region of an IgG1 heavy chain. Murine IFN-gamma R-IgG is secreted by transfected cells as a disulphide-bonded homodimer which binds IFN-gamma bivalently, with high affinity and in a species-specific manner. In vitro, mIFN-gamma R-IgG can block mIFN-gamma-induced antiviral activity and expression of the class I MHC antigen H-2Kk in cultured cells. In vivo, mIFN-gamma R-IgG can block the function of endogenous mIFN-gamma in mouse models of infection with Listeria monocytogenes and of contact sensitivity. These results show that mIFN-gamma R-IgG is an effective and specific inhibitor of mIFN-gamma both in vitro and in vivo. Thus, in general, IFN-gamma receptor immunoadhesins may be useful for investigating the biological functions of IFN-gamma as well as for preventing deleterious effects of IFN-gamma in human disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406584      PMCID: PMC1421939     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  Treatment of mice with human recombinant interleukin-2 augments resistance to the facultative intracellular pathogen Listeria monocytogenes.

Authors:  M Haak-Frendscho; K M Young; C J Czuprynski
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

2.  Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo.

Authors:  S Landolfo; F Cofano; M Giovarelli; M Prat; G Cavallo; G Forni
Journal:  Science       Date:  1985-07-12       Impact factor: 47.728

3.  Gamma-interferon: the match that lights the fire?

Authors:  A Billiau
Journal:  Immunol Today       Date:  1988-02

4.  Diverse approaches to new therapies may hold promise in multiple sclerosis.

Authors:  C A Raymond
Journal:  JAMA       Date:  1986-08-08       Impact factor: 56.272

5.  Effect of combined anti-gamma interferon antibody and cyclosporine therapy on cardiac allograft survival in the rat.

Authors:  R H Didlake; E K Kim; K Sheehan; R D Schreiber; B D Kahan
Journal:  Transplantation       Date:  1988-01       Impact factor: 4.939

Review 6.  The molecular cell biology of interferon-gamma and its receptor.

Authors:  M A Farrar; R D Schreiber
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

7.  IFN-gamma receptor-Ig fusion proteins. Half-life, immunogenicity, and in vivo activity.

Authors:  C Kürschner; L Ozmen; G Garotta; Z Dembic
Journal:  J Immunol       Date:  1992-12-15       Impact factor: 5.422

8.  Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA.

Authors:  M J Zoller; M Smith
Journal:  Nucleic Acids Res       Date:  1982-10-25       Impact factor: 16.971

9.  Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection.

Authors:  N A Buchmeier; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

10.  In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon.

Authors:  C O Jacob; P H van der Meide; H O McDevitt
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

View more
  3 in total

1.  Residue Trp-48 of Tva is critical for viral entry but not for high-affinity binding to the SU glycoprotein of subgroup A avian leukosis and sarcoma viruses.

Authors:  K Zingler; J A Young
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

2.  Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain.

Authors:  S A Marsters; D Pennica; E Bach; R D Schreiber; A Ashkenazi
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

3.  Immunomodulatory Effects of Taiwanese Neolitsea Species on Th1 and Th2 Functionality.

Authors:  Yin-Hua Cheng; Ying-Chi Lin; Ih-Sheng Chen; Sian-De Liu; Jih-Heng Li; Chia-Chi Wang
Journal:  J Immunol Res       Date:  2017-07-11       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.